Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

[video]Another Day, Another Big Pharma Breakup
Motley Fool
Friday, February 28, 2014 - 8:37am
tags:
Merck, consumer health, Bristol-Myers Squibb, Procter & Gamble, Novartis
Bayer Raises Drug Sales Forecast as Quarterly Profit Lags
Bloomberg
Friday, February 28, 2014 - 8:30am
tags:
Bayer, guidance, earnings
Arena's Belviq Sales To Hit $150 Million In 2014?
Seeking Alpha
Friday, February 28, 2014 - 8:29am
tags:
Belviq, obesity, Arena Pharmaceuticals, Eisai
Amarin Sues FDA Over Exclusivity for Fish Oil Pill
Bloomberg
Friday, February 28, 2014 - 8:26am
tags:
Amarin, FDA, Vascepa, exclusivity
Med tech industry backs a tax code reform that would repeal device tax
Fierce Medical Devices
Thursday, February 27, 2014 - 5:19pm
tags:
device tax, devices, Affordable Care Act
Radius Health looks to catch the IPO wave with $86M pitch
Fierce Biotech
Thursday, February 27, 2014 - 5:14pm
tags:
Radius Health, IPOs, osteoporosis
Drug firms argue against $1.2B Arkansas judgment
Yahoo/AP
Thursday, February 27, 2014 - 5:07pm
tags:
Arkansas, antipsychotics, JNJ, Janssen, Risperdal
The Vaccine Prevnar 13 And Its Competitor: Pfizer Vs. Merck
Seeking Alpha
Thursday, February 27, 2014 - 5:02pm
tags:
vaccines, Prevnar 13, Pfizer, Merck, Pneumovax
3 Stocks Boosting The Drugs Industry Higher
TheStreet.com
Thursday, February 27, 2014 - 5:00pm
tags:
Intercept Pharma, Amgen, Pfizer
Eli Lilly Gains Slightly on Dulaglutide Data
Yahoo/Zacks.com
Thursday, February 27, 2014 - 4:56pm
tags:
Eli Lilly, dulaglutide, diabetes
Why Mylan Is Getting A Great Deal Of Attention From Wall Street
Forbes
Thursday, February 27, 2014 - 4:54pm
tags:
Mylan, earnings, generics
The FDA Opens Its Vast Files on Drug Side Effects to the Public
Bloomberg/Businessweek
Thursday, February 27, 2014 - 4:52pm
tags:
FDA, side effects
Eliquis earns best safety score in its class in analysis of FDA adverse event reports
Fierce Pharma
Thursday, February 27, 2014 - 11:39am
tags:
Eliquis, FDA, Pfizer, Bristol-Myers Squibb
FDA spying may have broken whistleblower laws, congressional probe finds
Fierce Pharma
Thursday, February 27, 2014 - 11:31am
tags:
whistleblowers, FDA
Loss at BioMarin Narrower Than Expected
Yahoo/Zacks.com
Thursday, February 27, 2014 - 11:26am
tags:
earnings, Biomarin
3 Things to Watch When Isis Pharmaceuticals Reports 2013 Earnings
Motley Fool
Thursday, February 27, 2014 - 9:38am
tags:
Isis Pharmaceuticals, earnings
United Therapeutics Slips on Q4 Earnings Report
Yahoo/Zacks.com
Thursday, February 27, 2014 - 9:31am
tags:
earnings, United Therapeutics
Forest Labs submits NDA for Nebivolol and Valsartan combination in hypertension
Yahoo/Fly on the Wall
Thursday, February 27, 2014 - 9:30am
tags:
Forest Labs, Valsartan, Nebivolol, hypertension
FDA eases worries regarding certain diabetes medications
Yahoo/Fly on the Wall
Thursday, February 27, 2014 - 8:19am
tags:
FDA, diabetes, Merck, Januvia, Janumet, Novo Nordisk, Victoza, Bristol-Myers Squibb, Byetta, Bydureon
Valeant swings to profit on Bausch & Lomb buy
Yahoo/Reuters
Thursday, February 27, 2014 - 8:17am
tags:
Valeant Pharmaceuticals, earnings, Bausch & Lomb

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.